ARROWSTREET CAPITAL, LIMITED PARTNERSHIP
Position in TNDM — Tandem Diabetes Care Inc
CIK 1164508
BOSTON, MA
Position in TNDM
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$10,075,427
+$6,364,959 QoQ
Shares Held
667,689
+245.0% QoQ
Ownership
0.960%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#28
of 274 holders
Holding Since
Dec 2020
8 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TNDM Over Time
Shares Held
Position Value (USD)
Position in Medical Devices
Healthcare · as of Jun 30, 2026ARROWSTREET CAPITAL, LIMITED PARTNERSHIP holds $6,436,102,900 across 46 Medical Devices names. TNDM ranks #23 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SYK |
Stryker Corp
|
3,282,207 | $1,033,370,051 | |
| 2 | MDT |
Medtronic plc
|
12,892,710 | $1,008,596,703 | |
| 3 | BSX |
Boston Scientific Corp
|
23,293,913 | $994,184,206 | |
| 4 | ABT |
Abbott Laboratories
|
10,897,178 | $988,809,931 | |
| 5 | EW |
Edwards Lifesciences Corp
|
5,677,344 | $513,572,538 | |
| 6 | DXCM |
Dexcom Inc
|
6,873,273 | $462,914,936 | |
| 7 | PEN |
Penumbra Inc
|
834,903 | $263,620,622 | |
| 8 | STE |
STERIS plc
|
1,217,864 | $256,445,622 |
All Filings in TNDM
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10,075,427 | 667,689 | Shares | Defined | 2026-08-13 | |
| 2026-03-31 | $3,710,468 | 193,556 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $2,983,850 | 135,753 | Shares | Defined | 2026-02-13 | |
| 2025-06-30 | $231,341 | 12,411 | Shares | Defined | 2025-08-13 | |
| 2022-06-30 | $6,623,301 | 111,899 | Shares | Defined | 2022-08-15 | |
| 2022-03-31 | $1,103,708 | 9,491 | Shares | Defined | 2022-05-13 | |
| 2021-03-31 | $8,662,796 | 98,162 | Shares | Defined | 2021-05-14 | |
| 2020-12-31 | $11,011,237 | 115,084 | Shares | Defined | 2021-02-12 | |
| No filing history on record for this holder in this stock. | ||||||